By Brad Sorensen, CFA
NASDAQ:LGVN
READ THE FULL LGVN RESEARCH REPORT
Longeveron (NASDAQ:LGVN) is a clinical-stage biotechnology company that has positioned itself in the regenerative medicine space with a potentially life-changing therapeutic candidate. Its flagship product, laromestrocel, is an allogeneic medicinal-signaling cell (MSC) therapy derived from young healthy adult donors and manufactured under current good manufacturing practice. The science behind laromestrocel rests on the idea that these MSCs may provide anti-inflammatory, pro-vascular, and regenerative support in tissues that are damaged or under stress. The company behind these exciting developments is at an inflection point in our view, with a good opportunity to achieve many of the goals discussed in the near future.
While the company is advancing multiple clinical programs (including efforts in Alzheimer’s disease and age-related frailty), the HLHS program stands out for both its compelling early data and regulatory momentum.
Although treating HLHS is the primary condition Longeveron is focused on, it certainly isn’t the only one. Company management recently announced results from its Phase 2b clinical trial using laromestrocel as a treatment for Age-Related Frailty. Age-Related Frailty is a clinical condition seen most commonly in older adults that reflects a decline in physiological reserves across multiple body systems. It’s not a single disease but a syndrome marked by weakness, fatigue, slow walking speed, unintentional weight loss, and reduced ability to cope with stressors like illness or injury. People living with frailty are more vulnerable to falls, disability, hospitalizations, and loss of independence because their bodies can’t respond as effectively to challenges as they once could. Estimates of how many people suffer from frailty vary depending on the definition used and the population studied, but research indicates that in community-dwelling older adults (typically defined as age 65 and older), about 7–16% are frail using commonly accepted criteria, a significant number of people. Trial results from Longeveron showed that laromestrocel improved the physical condition of patients with frailty after nine months compared with placebo. The main data point is the 6-minute walk test, which saw a meaningful 63-meter improvement compared to placebo, which is a substantial improvement and indicates great promise that laromestrocel can improve the lives of thousands of patients.
We also want to remind investors of the progress made on treating HLHS, which is a rare and life-threatening congenital heart defect in which the left ventricle is severely underdeveloped or absent, meaning that the right ventricle must be adapted to handle systemic circulation. Even with the standard of care—typically a series of three reconstructive surgeries over the first few years of life—survival into adolescence is only around 50–60%.
Longeveron’s approach has been to administer laromestrocel directly into the right ventricle (or the myocardium of the right ventricle) during the second stage of surgery (the “Glenn” procedure, typically at around 4 months of age). Company scientists believe that by improving the function of the systemic right ventricle—through regenerative mechanisms—the therapy should improve transplant-free survival and long-term outcomes for these infants.
The company reported Phase 1 results (called ELPIS I) in ten infants. In that study, laromestrocel was well tolerated: there were no major adverse cardiovascular events or infections related to therapy through one year, meeting the primary safety endpoint. Even more striking, long-term follow-up showed 100 % transplant-free survival up to five years in those patients, compared to historical controls (approximately 83 % at five years, with ~5 % requiring transplant) in the comparable population.
Building on that, Longeveron is now conducting a pivotal Phase 2b trial (ELPIS II). The trial is designed to compare Laromestrocel plus standard surgery versus standard surgery alone, with endpoints including survival at 12 months, length of hospitalization, and change in right ventricular ejection fraction between baseline and 12 months. Full enrollment was achieved in June 2025, with topline results, as mentioned above, anticipated in the third quarter of 2026 after a 12-month follow-up.
On the regulatory front, the program has very strong designations. The U.S. Food and Drug Administration has approved three special designations for laromestrocel in the HLHS indication: Rare Pediatric Disease (RPD) designation, Orphan Drug Designation (ODD), and Fast Track designation. Importantly, following a Type C meeting with the FDA in September 2024, the agency confirmed that the ELPIS II trial could serve as a pivotal study—and if positive, could form the basis for a Biologics License Application (BLA) submission for full traditional approval.
Company management continues to push the company forward, recently announcing that LGVN has licensed a patent from the University of Miami that protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells. In plain English, these cells are able to differentiate into human cardiac muscle cells. This creates the potential for a treatment that is safer than existing techniques to derive new cardiac heart muscle cells. This move by management appears to us to be a perfect complement to the company’s existing treatment line and should advance the company’s ability to treat devastating heart conditions.
That’s not the only line of treatment being pursued by the company as management recently announced that it completed a “positive” Type B Meeting with the FDA regarding advancing laromestrocel for the purpose of treating Alzheimer’s Disease. During the meeting, the FDA and the company reached alignment on the study design for a single, pivotal, seamless adaptive Phase 2/3 clinical trial. Additionally, something we always like to hear about the approval process, the FDA agreed to consider a Biological License Application (BLA) based on positive interim trial results, which accelerates the path to what we believe will be the approval of laromestrocel as a treatment for Alzheimer’s.
As a reminder, our optimism is well-founded based on trial results that we’ve written about recently. For example, the Phase 2a CLEAR-MIND study results showed a favorable safety profile, absence of amyloid-related imaging abnormalities (ARIA) with Laromestrocel TM administration, and several domains of potential clinical efficacy, including cognition, function, quality of life, and reduction in brain atrophy. The results of the CLEAR-MIND trial formed the basis for the FDA RMAT designation. Another reminder that the RMAT designation is an important milestone, allowing the company better access to the FDA and accelerating the pathway to approval.
Summary
We continue to believe that Longeveron is an exciting clinical-stage company, and investors aren’t appropriately appreciating the game-changing potential laromestrocel may be able to have on multiple serious medical conditions. As a result of the prudent decisions made by management, we believe laromestrocel will ultimately have a substantial impact on the health situations of thousands of patients. We believe the stock continues to be underpriced as investors aren’t appreciating the potential of laromestrocel and encourage investors to take a look at LGVN.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.